Eylea is a recombinant fusion protein consisting of portions of human VEGF receptors formulated for intravitreal injection. It acts by providing a false receptor that binds VEGF-A and PIGF.
How Does Eylea Work?
Eylea works by inhibiting the vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PIGF). VEGF-A is angiogenic factor that acts via tyrosine kinases VEGFR-1 and VEGF-2 on the surface of endothelial cells. PIGF acts by binding to VEGFR-1. Activation of these receptors can result in neovascularization (growth of new abnormal blood vessels) and vascular permeability (leaking of blood vessels). This leads to the development of neovascular age-related macular degeneration or the wet type of macular degeneration.
Reason for Using Eylea
Eylea is indicated for the treatment of patients with neovascular age-related macular degeneration or wet type of macular degeneration.
Contraindications for Eylea
Eylea is contraindicated in patients with known hypersensitivity to Eylea or any of its components.
Ocular or Periocular Infections
Eylea is contraindicated in patients with ocular or periocular infections.
Eylea is contraindicated in patients with any active ocular inflammation.
Side Effects and Precautions for Eylea
Endophthalmitis has been reported with intravitreal injections. Proper sterile technique and the use of topical antibiotics should be used.
Retinal detachments have been reported with intravitreal injections. Patients should be warned about any symptoms of a retinal detachment and to call the doctor’s office if any of these symptoms appear.
Arterial thromboembolic events can occur following the intravitreal injections. This occurs in less than 2 % in patients.
Increased Intraocular Pressure
Acute and persistent increase in intraocular pressure can occur following the injection of Eylea. The intraocular pressure should be monitored in patients who are receiving Eylea intravitreal injections.
Others Side Effects Secondary to Eylea Injections
These include conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, eye redness, corneal erosion, detachment of the retinal pigment epithelium, injection site pain, foreign body sensation, tearing, blurred vision, eyelid edema, and corneal edema.
Administration and Strength of Eylea
The intravitreal injection should be done in a sterile manner using topical anesthesia. The intraocular pressure should be monitored after the injection. The recommended dosage is Eylea 2 mg injected intravitreally every 4 weeks for the first 3 months and followed by 2 mg injected every 8 weeks. The administration can be varied by the eye doctor depending on the clinical course.
How is Eylea Supplied?
Eylea is supplied in a sterile single-use glass vial containing 0.278 mL of 40mg/mL solution.